| Autor: |
Rahman M; Department of Biotechnology and Genetic Engineering, Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj, Bangladesh., Rakhi NN; Department of Biotechnology and Genetic Engineering, Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj, Bangladesh. nadiranrakhi@gmail.com. |
| Jazyk: |
angličtina |
| Zdroj: |
Advances in respiratory medicine [Adv Respir Med] 2021; Vol. 89 (1), pp. 90-91. Date of Electronic Publication: 2021 Feb 09. |
| DOI: |
10.5603/ARM.a2020.0191 |
| Abstrakt: |
Since December 2019, the rapid spread of SARS CoV-2 across the border, shuffled into a world pandemic situation with an alarming rate of morbidity and mortality. Concerns are mounting as the reports indicate tangled circumstances among the COVID-19 patients due to blood coagulopathy followed by organ dysfunction. COVID-19 induced an alteration in coagulation function increase the risk of pulmonary embolism and deep vein thrombosis associated with poor prognosis as well as high mortality. An elevated level D-dimer and other fibrin degrading protein are documented among the patients with COVID-19; especially in severe cases. Differences in coagulopathy among severe and non-severe cases, required prompt attention to adopt a more effective management strategy. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
